Gapping up
In reaction to earnings/guidance:
- TSM +3.8%, UNH +2.7%, BAC +2.2%, WBA +1.8%, WFC +1.7%, MS +1.7%
Other news:
- NRXP +40.7% (announces the publication of results from trial of aviptadil for the treatment of respiratory failure in patients with Critical COVID-19)
- GMED +8.7% (files patent infringement lawsuit against Life Spine)
- STRL +6.8% (wins $40.4 mln aviation project at Utah airport)
- WDFC +4.8% (approves new $75 mln share repurchase authorization)
- HYZN +4.4% (expects capacity at its European facility to increase to up to 1000 trucks per year in 2022)
- BCLI +4.1% (Phase 2 Clinical Trial Data of NurOwn in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis)
- VET +2.7% (achieves certification under the EO100 standard for three natural gas sites in Canada)
- SVM +2.4% (to acquire Kaunping silver-lead-zinc-gold project in China for $13.5 mln)
- FBIO +2.3% (reports clinical data for CUTX-101 at American Academy of Pediatrics National Conference & Exhibition)
- OXY +2% (to sell interests in Ghana offshore fields for $750 mln)
- TPTX +1.7% (announces collaboration with EQRx)
- NGD +1.5% (reports operational results for Q3)
- FTI +1.4% (completes acquisition of Magma Global)
- WGO +1.1% (authorizes $200 mln share repurchase authorization)
- MTRX +1% (awarded multiple contracts worth $50 mln for electrical infrastructure work)
- GOLD +1% (set to achieve 2021 production targets)
- LULU +0.9% (gets into footwear with a new design according to Business Insider)
- CNK +0.9% (names new CFO)
Analyst comments:
- DK +5.3% (upgraded to Buy from Neutral at Goldman)
- E +1.5% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)